乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ASCO

<乌鸦传媒>Psychosocial Interventions Help Cancer Patients Cope

Programs focus on lowering fear of recurrence, managing advanced disease

<乌鸦传媒>ASCO: Healthy Lifestyle Adds to Colon Cancer Survival

Study results should not be interpreted as substitutes for standard care

<乌鸦传媒>ASCO: HPV Vax Averts Oral Infections in Young Adults

But low uptake did limit impact

<乌鸦传媒>New Standard for Older Patients With Glioblastoma

Radiation plus temozolomide extends survival

<乌鸦传媒>Pembrolizumab Plus Lenalidomide Gets Response in MM

Combo shows signs of benefit in relapsed/refractory myeloma

<乌鸦传媒>Novel Agent Promising in Pretreated Myeloma

Phase II trial shows 18-month median survival with isatuximab

<乌鸦传媒>Plitidepsin Shows Activity in Multiple Myeloma

Early data favorable for sea squirt drug

<乌鸦传媒>Practice Changer: Tandem Transplant for Neuroblastoma

13% absolute increase in 3-year event-free survival

<乌鸦传媒>New Trial 'Justifies' FDA Nod for Ibrance

Phase III study had almost identical results as pivotal trial

<乌鸦传媒>Widely Used Breast Chemo Regimen Falls Short

Taxane-cyclophosphamide regimens fail against taxane-anthracycline combinations

<乌鸦传媒>Study: Minorities Less Likely to Get Ca Risk Management

Less genetic testing, bilateral mastectomy in black BRCA carriers

<乌鸦传媒>Novel App Seems to Extend Lung Cancer Survival

Web app offers early detection of relapse, complications between healthcare visits

<乌鸦传媒>Combo Boosts PFS in Tough-to-Treat Myeloma

Recurrent or relapsed disease susceptible to daratumumab-bortezomib-dexamethasone

<乌鸦传媒>Revlimid Maintenance Benefits Multiple Myeloma

Prolonged overall survival in patients post-autologous stem cell transplant

<乌鸦传媒>Longer Letrozole Equals Less BRCA Recurrence

Study suggests that 10 years is better than five

<乌鸦传媒>Antibody Shines in Advanced Gastric Cancer

IMAB362 leads to longer remission, better survival

<乌鸦传媒>Novel Agent Offers Hope in Small Cell Lung Cancer

Antibody-drug conjugate Rova-T looks good, but in very early trial

<乌鸦传媒>ASCO: Extended Femara Therapy Ups DFS in Breast Cancer

Video discusses study showing AI benefit to 10 years

<乌鸦传媒>Gemcitabine-Capecitabine Tx: The New Standard in Pancreatic Ca?

Five-year survival reaches all-time high in post-surgical patients

<乌鸦传媒>Adjuvant Chemo a Winner in Rare Brain Cancer

Significant survival bump in nondeleted anaplastic glioma

<乌鸦传媒>Trastuzumab Biosimilar Shows Similar Effects

Near-copy of Herceptin may improve global access to treatment

<乌鸦传媒>Palliative Care Benefits Caregivers, Too

Better QoL, less depression among 'downstream' effects

<乌鸦传媒>Transplant Remains King for New Myeloma

Significant improvement in PFS versus systemic treatment

<乌鸦传媒>Bone Drugs Equal as Breast Cancer Therapies

Little difference seen among bisphosphonates as cancer fighters.

<乌鸦传媒>How ASCO'S First Clinical Trial -- TAPUR -- Came To Be

ASCO's entry will evaluate off-label use of targeted agents

<乌鸦传媒>ASCO: Gazyva Doubles Average Remission Time in NHL

Obinutuzumab delays progression in rituximab-refractory indolent disease.

<乌鸦传媒>Ibrance Delivers in Advanced Breast Ca

Palbociclib-fulvestrant combo leads to better PFS as second-line therapy

<乌鸦传媒>ASCO: Annual Meeting Emphasizes Advances, Challenges in Cancer

Largest program to date highlights developments in breast cancer, other malignancies

<乌鸦传媒>ASCO: Chemo-ADT Combo Still Winning in Prostate Cancer

Yet another report of survival improvement with upfront docetaxel plus hormonal therapy.

<乌鸦传媒>ASCO: Myeloma Study Results Inconclusive

CHICAGO -- A trial comparing two immunomodulatory regimens for myeloma failed to demonstrate noninferiority for the newer drug.

<乌鸦传媒>ASCO: Combo Extends PFS in Relapsed Myeloma

CHICAGO -- Progression-free survival in relapsed/refractory myeloma increased significantly in patients treated with a three-drug regimen that included panobinostat versus a two-drug regimen, a randomized trial showed.

<乌鸦传媒>ASCO: Targeting PD-1 Works in Advanced Melanoma

CHICAGO -- Two studies indicate that using investigative immunotherapy drugs improves survival and response in patients with metastatic melanoma, researchers said here.

<乌鸦传媒>ASCO: Antibody Adds 6 Weeks to Squamous NSCLC Survival

CHICAGO -- The novel anti-EGFR monoclonal antibody necitumumab modestly improved survival in squamous non-small cell lung cancer (NSCLC) in a pivotal trial, but many called the effect too small to count.

<乌鸦传媒>ASCO: Targeted Combo Extends PFS in Ovarian Ca

CHICAGO -- Progression-free survival almost doubled in women with platinum-sensitive relapsed ovarian cancer treated with two targeted drugs instead of one, investigators reported here.

<乌鸦传媒>ASCO: Ipilimumab Cuts Relapse but Safety Issues Remain

CHICAGO -- High-risk melanoma patients have a reduced level of relapse if they are taking the monoclonal antibody ipilimumab (Yervoy) when compared with placebo, researchers said here.

<乌鸦传媒>ASCO: Vinegar Test May Reduce Cervical Ca Deaths

CHICAGO -- Vinegar has been used for everything from cleaning refrigerators to taming foot odors, and now this common kitchen staple may reduce cervical cancer deaths as well, researchers reported here.

<乌鸦传媒>ASCO: Targeted Agent Has Slim NSCLC Benefit

CHICAGO -- The novel kinase inhibitor nintedanib may slightly delay relapse of non-small cell lung cancer when added to chemotherapy, with perhaps greater benefit in adenocarcinomas, the LUME-Lung 1 trial showed.

<乌鸦传媒>ASCO: Herpes-Derived Tx for Melanoma?

CHICAGO -- Intralesional injection of an oncolytic therapy significantly increased the durable response rate in advanced melanoma compared with a control therapy, according to results of a randomized trial.

<乌鸦传媒>ASCO: Immune Therapy Durable in Melanoma

CHICAGO -- A therapy aimed at reviving the immune response to advanced melanoma generated durable responses in long-term follow-up of an early clinical trial, a researcher said here.

<乌鸦传媒>ASCO: Targeted Rx Slows Ovarian Ca Progression

CHICAGO -- Adding the oral anti-angiogenesis drug pazopanib (Votrient) to chemotherapy extended disease-free survival by an average of 5.6 months, a phase III study showed.

5